Based on the AstraZeneca PLC stock forecast from 0 analysts, the average analyst target price for AstraZeneca PLC is not available over the next 12 months. AstraZeneca PLC’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AstraZeneca PLC is Bullish , which is based on 4 positive signals and 1 negative signals. At the last closing, AstraZeneca PLC’s stock price was GBX 11,606.00. AstraZeneca PLC’s stock price has changed by -2.85% over the past week, +0.35% over the past month and +10.05% over the last year.
No recent analyst target price found for AstraZeneca PLC
No recent average analyst rating found for AstraZeneca PLC
Company Overview AstraZeneca PLC
N/A
N/A
N/A
N/A
GBX
UK
Adjusted Closing Price for AstraZeneca PLC (AZN:LSE)
Loading...
Unadjusted Closing Price for AstraZeneca PLC (AZN:LSE)
Frequently Asked Questions About AstraZeneca PLC (AZN:LSE) Stock
Stock Target Advisor's fundamental analysis for AstraZeneca PLC's stock is Bullish .
Unfortunately we do not have enough data on AZN:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AZN:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AZN:LSE's stock to indicate if its overvalued.
The last closing price of AZN:LSE's stock was GBX 11,606.00.
Unfortunately we do not currently have any market capitalization data for AZN:LSE's stock.
Unfortunately we do not have enough analyst data on AZN:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AstraZeneca PLC's stock.
Sorry, we do not have any data on the number of employees for AstraZeneca PLC.
Sorry we do not have any infomation available on AstraZeneca PLC's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Frequently Asked Questions About AstraZeneca PLC (AZN:LSE) Stock
Stock Target Advisor's fundamental analysis for AstraZeneca PLC's stock is Bullish .
Unfortunately we do not have enough data on AZN:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AZN:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on AZN:LSE's stock to indicate if its overvalued.
The last closing price of AZN:LSE's stock was GBX 11,606.00.
Unfortunately we do not currently have any market capitalization data for AZN:LSE's stock.
Unfortunately we do not have enough analyst data on AZN:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains AstraZeneca PLC's stock.
Sorry, we do not have any data on the number of employees for AstraZeneca PLC.
Sorry we do not have any infomation available on AstraZeneca PLC's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AZN:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
